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Introduction: AZD6244 (ARRY-142886) is a potent, selective
MEK inhibitor. This study aimed to evaluate the efficacy and safety
of AZD6244 versus pemetrexed as second- or third-line treatment in
patients with advanced non-small cell lung cancer (NSCLC).
Methods: In this randomized phase II study, patients received either
100 mg oral AZD6244 free-base suspension twice daily or 500
mg/m2 intravenous pemetrexed once every 3 weeks after pretreat-
ment with a corticosteroid, folic acid, and vitamin B12. The primary
end point of the study was the disease progression event count.
Results: Eighty-four patients were randomized. Disease progression
events were experienced by 28 (70%) and 26 (59%) patients in the
AZD6244 and pemetrexed groups, respectively. Median progres-
sion-free survival was not statistically significantly different be-
tween the AZD6244 and pemetrexed groups (67 versus 90 days,
respectively; hazard ratio 1.08, two-sided 80% confidence inter-
val  0.75–1.54; p  0.79). Two patients in the AZD6244 group
had a best response to treatment of partial response. In the pem-
etrexed group, one patient achieved a complete response and one
patient a partial response. Dermatitis acneiform, diarrhea, nausea,
and vomiting were the most frequently reported adverse events with
AZD6244, compared with fatigue, anemia, nausea, anorexia, and
dermatitis acneiform with pemetrexed.
Conclusions: Oral AZD6244 showed clinical activity as second- or
third-line therapy for patients with advanced NSCLC. In an uns-
elected NSCLC population, there is no suggestion that AZD6244
monotherapy offers any advantage over standard treatment with
pemetrexed. Based on preclinical data and recent clinical observa-
tions, further development of AZD6244 in NSCLC should focus on
BRAF or RAS mutation-positive patients and/or AZD6244-based
combination regimens.
Key Words: AZD6244, Non-small cell lung cancer, Phase II,
Clinical trial, MEK inhibitor.
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Lung cancer is the leading cause of cancer-related deathworldwide, and in the US alone, 219,440 new cases and
159,390 deaths are forecast in 2009 (28% of all cancer
deaths).1 The 5-year survival rate for all stages combined
is just 15%.2 Non-small cell lung cancer (NSCLC) ac-
counts for approximately 85% of all lung malignancies,2
and the majority of patients present with advanced, unre-
sectable disease. Median survival time for these patients is
less than 1 year using current standard of care platinum-
based chemotherapeutic regimens,3,4 and treatment of ad-
vanced disease therefore remains a difficult challenge. The
introduction and integration of new targeted therapies into
the clinical setting promises a new era in the treatment of
NSCLC.
The RAS/RAF/MEK/ERK signaling cascade plays an
important role in the regulation of processes such as cell prolif-
eration and survival.5 Aberrant signaling triggered by mutations
within the pathway, frequently within the RAS and RAF onco-
genes, may contribute to the malignant progression of many
human cancers.6 In the case of NSCLC, KRAS oncogene mu-
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tations, for example, occur in approximately 25% of cas-
es.7,8 Mitogen-activated protein kinase kinases 1 and 2
(MEK1/2) are attractive therapeutic targets for cancer
treatment because of their key position within the Ras/Raf/
MEK/ERK pathway. MEK1/2 are situated downstream of
Ras and Raf, and furthermore, the only known substrates
of MEK1/2 phosphorylation are the extracellular signal-
regulated kinases 1 and 2.
AZD6244 is an orally available, potent, selective,
ATP-uncompetitive inhibitor of MEK1/2 and has demon-
strated activity in preclinical models in a variety of tu-
mors.9 A phase I clinical trial has established that
AZD6244 is well tolerated with a manageable safety
profile and has identified 100 mg twice daily as the most
suitable dose for subsequent phase II trials because this
dose results in target inhibition.10 Pemetrexed (Alimta; Eli
Lilly and Company, Indianapolis, IN) is approved and
widely used for second- or third-line treatment of ad-
vanced NSCLC,11 having demonstrated comparable clini-
cal efficacy and improved safety when compared with
docetaxel in patients with NSCLC previously treated with
chemotherapy.12 In this study, we evaluated the efficacy
and safety of AZD6244 versus pemetrexed as a second-/
third-line treatment in patients with advanced NSCLC.
PATIENTS AND METHODS
Patient Selection
Eligible patients were aged 18 years with histologi-
cally or cytologically confirmed NSCLC who had previously
received one or two chemotherapeutic regimens, had a World
Health Organization performance status 0 to 2, and had a life
expectancy 12 weeks. Patients were suitable for treatment
with pemetrexed and had adequate hepatic (total bilirubin
1.5  upper limit of normal [ULN] and alanine amino-
transferase and aspartate aminotransferase 2.5  ULN
irrespective of whether liver metastases present) and renal
(creatinine clearance 45 ml/min and serum creatinine
1.25  ULN) function and adequate bone marrow reserve
(platelets 100,000/l, hemoglobin 10 g/dl, and absolute
neutrophil count 1500/l). Prior surgery and/or local irra-
diation were allowed, but previous therapy with a MEK
inhibitor or pemetrexed was not permitted.
This study was performed in accordance with ethical
principles that have their origin in the Declaration of Helsinki
and are consistent with the International Conference on Har-
monization/Good Clinical Practice. All patients gave written
informed consent.
Study Objectives
The primary objective of this study was to evaluate the
efficacy of AZD6244 versus pemetrexed in the second- or
third-line treatment of advanced NSCLC by assessment of
disease progression. The secondary objective of the study
was to assess the safety and tolerability of AZD6244 in the
treatment of NSCLC by review of adverse events (AEs) and
laboratory parameters.
Study Design
This was a phase II, multicenter, open-label, random-
ized, two-arm, parallel-group study. Patients were random-
ized in a 1:1 ratio to receive either 100 mg oral AZD6244
free-base suspension twice daily or 500 mg/m2 pemetrexed
by intravenous infusion over 10 minutes every 3 weeks.
Patients in the pemetrexed group received premedication with
a corticosteroid and vitamin supplementation with folic acid
and vitamin B12. Patients were not required to have measur-
able disease (defined by Response Evaluation Criteria in
Solid Tumors [RECIST]13) at baseline.
AZD6244 dose reductions were permitted, initially
to 50 mg twice daily and then to 50 mg once daily. Dose
reductions below 50 mg once daily were not allowed, and
dose re-escalation was not permitted. Pemetrexed dose
reductions were allowed to manage hematologic toxicity as
part of routine clinical practice. Patients continued to
receive AZD6244 or pemetrexed until objective and/or
clinical progression were observed, provided they were
deriving clinical benefit, and there was no unacceptable
toxicity. At the investigators’ discretion, patients who
discontinued treatment could proceed with other treat-
ments or participate in other studies.
Assessments
The adopted study design removed, as far as possible,
the need for regular tumor assessments of disease status to
simplify the study with regard to data collection and fre-
quency of assessments. Therefore, tumor assessments were
performed at screening and then per site clinical practice.
There was a mandatory tumor assessment for all patients who
had not previously progressed at a fixed calendar date 3
days. A physical examination was given to all patients at
screening and then every 3 weeks (3 days) from week 3
onward. Because tumor response was not an end point of the
study, confirmation of response by repeat tumor measure-
ments was not required by the study protocol. Disease pro-
gression was assessed using RECIST. Objective progression
was defined as 20% increase in the sum of longest diame-
ters of measurable lesions, presence of new lesions, or un-
equivocal progression of nonmeasurable lesions. Lesions in
previously irradiated areas were considered evaluable for
progression. Clinical disease progression was defined as a
global deterioration of health status requiring discontinuation
of treatment as a result of the underlying disease and not due
to intercurrent illness or adverse effects from therapy. All
safety data were based on the event-free survival (EFS)
population (all patients who received at least one dose of
study medication). Patients were evaluated for AEs through-
out the study (at weeks 1–3 and then every 3 weeks while on
study treatment until data cutoff) and until 30 days after study
drug discontinuation. All AEs were graded according to
the Common Terminology Criteria for Adverse Events
(CTCAE), Version 3.0.
Statistical Analyses
The study was designed as a randomized exploratory
study to quantify the level of risk entailed for further devel-
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opment,14 and the aim was to identify whether there was a
clear signal of activity of AZD6244 in advanced NSCLC.
The proportion of patients experiencing a disease progression
event on or before the data cutoff point was compared
between the treatment arms using a logistic regression model,
with a complementary log-log function and including a factor
for treatment group. Results were approximated as a hazard
ratio (HR) and reported with the corresponding confidence
interval (CI) and p value. Disease progression event count has
been shown to be a good assessment for phase II decision
making,15,16 because it does not rely on time-dependent
events that may overestimate progression times and poten-
tially introduce bias when comparing treatments. Analysis of
progression event count requires less intensive monitoring of
patients and provides an unbiased estimate of the HR. A
progression event was defined as the earliest of (i) objective
and/or clinical progression on or before the data cutoff point,
as measured using RECIST, or (ii) death by any cause. The
timing of the analysis (i.e., data cutoff) was guided by the
target number of patients with a disease progression event. A
total of 38 progression events would ensure that the study had
at least 80% power to detect a true HR of 0.50 at the
two-sided 20% significance level. As such, a result from this
study would be considered statistically significant if the
two-sided p value was less than 0.2. Therefore, a minimum of
64 patients were required and the data cutoff was set when
approximately 60% of patients had experienced disease pro-
gression events. The analysis was performed on an intent to
treat (ITT) basis using the ITT analysis set (all randomized
patients), and patients were analyzed according to their ran-
domized study drug. Taking into account the timing of a
progression event (as assessed by the investigator), an ex-
ploratory analysis was also performed in support of the
progression-event count analysis. This analysis and the in-
vestigator’s assessed best response were not robust, because
the protocol did not require regular tumor assessments or
patients to have measurable disease at baseline.
RESULTS
Demographic and Baseline Characteristics
Eighty-four patients from 10 centers (4 in the US, 4 in
Bulgaria, and 2 in Romania) were randomized to study
treatment (40 and 44 patients in the AZD6244 and pem-
etrexed treatment groups, respectively; Figure 1), and these
comprised the ITT population. Both treatment groups were
generally comparable with respect to demographic and base-
line characteristics (Table 1).
Efficacy
In the ITT analysis set, 28 (70%) patients in the
AZD6244 group compared with 26 (59%) patients in the pem-
etrexed group had a disease progression event. The resulting HR
was 1.35, and this difference was not statistically significantly
different as p 0.2 (two-sided 80% CI 0.93–1.94; two-sided
95% CI  0.77–2.36; p  0.30).
There was no significant difference between the two
treatment groups in terms of progression-free survival (PFS)
FIGURE 1. AZD6244 versus pem-
etrexed study design.
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in the ITT population (Figure 2). Median PFS in the ITT
analysis set was 90 days in the pemetrexed treatment arm
compared with 67 days in the AZD6244 group (HR 
1.08; two-sided 80% CI  0.75–1.54; two-sided 95% CI 
0.62–1.86; p  0.79). The majority of patients were treated
until progression. Given that the protocol did not require
regular tumor assessments, it is possible that the time
to progression may have been overestimated for some
patients.
In total, four patients (two in each treatment group) in
both the ITT and EFS populations achieved a best overall
response according to RECIST of complete or partial re-
sponse at the time of the mandatory tumor assessment
(Table 2). In the pemetrexed group, one patient had a
complete response and one had a partial response (total
treatment duration of 53 days for both patients). In the
AZD6244 group, two patients achieved a partial response
with total treatment durations of 76 and 78 days, respec-
tively. All the four patients were still receiving treatment
at the time of the mandatory tumor assessment. However,
the protocol did not require regular tumor assessments;
therefore, an interim scan may potentially have identified
patients who had a better tumor response than that reported
here. Furthermore, patients were not required to have
measurable disease at baseline.
Safety
Median actual exposure to AZD6244 and pemetrexed
was 63 and 61 days, respectively, at the time of data cutoff.
Treatment was discontinued in the majority of patients before
data cutoff (75% and 61% in the AZD6244 and pemetrexed
treatment groups, respectively), primarily as a result of dis-
ease progression. Ten (25%) patients in the AZD6244 group
and eight (20%) patients in the pemetrexed group experi-
enced AEs that led to dose reduction, dose interruption, or
treatment discontinuation.
The majority of patients in both treatment groups
experienced 1 AE causally related to treatment (28
[70%] patients and 29 [71%] patients in the AZD6244 and
pemetrexed groups, respectively), and the majority were of
mild to moderate severity. The most common treatment-
related AEs reported in the AZD6244 group were derma-
titis acneiform and diarrhea (Table 3). The most frequently
observed treatment-related AEs with pemetrexed were
fatigue, anemia, and nausea.
Treatment-related serious adverse events were experi-
enced by three patients in the pemetrexed group (secondary
myelodysplastic syndrome in one patient and neutropenia in two
patients [one patient had two serious adverse events of neutro-
penia]) and by one patient in the AZD6244 group (respiratory
failure, resulting in patient death).
A total of 8 (20%) deaths were recorded in each
treatment group before study termination (30 days after the
last dose of study treatment for an individual patient), the
majority of which were the result of disease progression or
AEs related to NSCLC that could be expected in a popu-
lation with advanced NSCLC and its associated comor-
bidities. One patient in the pemetrexed treatment group
died because of an AE of myocardial infarction. The fatal
AE of respiratory failure in the AZD6244 group was
considered by the investigator to be potentially related to
AZD6244 study treatment. This patient was a 33-year-old
female nonsmoker diagnosed with adenocarcinoma. Onset
of constant CTCAE grade 3 dyspnoea that was considered
possibly related to AZD6244 treatment occurred 6 days
after starting the treatment. The event of dyspnoea wors-
ened to CTCAE grade 4 that day, and treatment was
permanently discontinued. The patient’s condition contin-
ued to deteriorate, resulting in hospitalization on day 18,
and she died of respiratory failure after 24 days. The
investigator considered disease progression to be the likely
cause of death; however, a computed tomography scan
TABLE 1. Demographic Characteristics (ITT Population)
Characteristics
Patients, n (%)
AZD6244
(n  40)
Pemetrexed
(n  44)
Age (yr)
Mean (SD) 59.2 (12.58) 62.7 (8.35)
Median (range) 61.5 (21–79) 63.5 (43–80)
Sex
Male 26 (65) 27 (61)
Female 14 (35) 17 (39)
Race
Caucasian 39 (98) 42 (95)
Black 1 (3) 1 (2)
Other 0 1 (2)
Region
Europe 24 (60) 28 (64)
USA 16 (40) 16 (36)
Number of previous therapies
One 31 (78) 35 (80)
Two 9 (23) 9 (20)
Previous treatments
High-dose radiationa 13 (33) 18 (41)
Platinum therapy 37 (93) 42 (95)
Taxane therapy 18 (45) 21 (48)
EGFR inhibitor therapy 1 (3) 1 (2)
Responded to EGFR inhibitor therapy 1 (3) 1 (2)
Diagnosis of adenocarcinoma 15 (38) 20 (45)
Time since diagnosis of advanced disease
1 yr 29 (73) 35 (80)
1 yr 11 (28) 9 (20)
Smoking statusb
Nonsmoker 6 (15) 12 (27)
Ex-smoker 18 (45) 18 (41)
Occasional smoker 0 0
Habitual smoker 16 (40) 14 (32)
Pack-yearsc
Mean (SD) 30.1 (22.50) 25.6 (20.99)
Median (range) 30.0 (0–99) 26.5 (0–75)
a High-dose radiation was defined as 60 Gy.
b Smoking status was defined as nonsmoker (never smoked), ex-smoker (no
cigarettes smoked in last 6 mo), occasional smoker (1 cigarette per day), or habitual
smoker (1 cigarette per day).
c A pack-year was defined as 20 cigarettes/d/yr.
EGFR, epidermal growth factor receptor.
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performed after admission to hospital did not show clear
evidence of disease progression. As a result, the investi-
gator could not eliminate the possibility that the respira-
tory failure was causally related to treatment with
AZD6244.
Laboratory and Clinical Parameters
Both AZD6244 and pemetrexed were associated with
small mean increases in alanine aminotransferase and aspartate
aminotransferase within normal ranges. Treatment with
AZD6244 was associated with fewer clinically relevant changes
in hematology variables compared with pemetrexed. Sixteen
(43%) patients who received AZD6244 experienced CTCAE
grade 1–2 decrease in hemoglobin level, compared with 25
(63%) patients in the pemetrexed group with CTCAE grades 1
to 4. Decrease in white blood cells, neutrophils, and platelets
count was experienced by 3% (n 1), 5% (n 2), and 3% (n
1) of patients in the AZD6244 group, compared with 53% (n
21), 48% (n  19), and 23% (n  9) of patients in the
pemetrexed group. Overall, no new safety concerns for
AZD6244 were identified from the hematology and clinical
chemistry results.
DISCUSSION
In this phase II signal searching study in a broad popula-
tion of pretreated patients with advanced NSCLC, AZD6244 did
not demonstrate superiority to pemetrexed in terms of efficacy.
However, no significant differences between the two treatment
arms were observed in terms of the proportion of patients with
TABLE 2. Investigators’ Assessment of Best Overall
Response in Accordance with RECIST (ITT Population)a
Randomized
Treatment n
Patients, n (%)
Complete
Response
Partial
Response
Stable
Disease
Progressive
Disease
Not
Evaluable
AZD6244 40 0 2 (5) 14 (35) 18 (45) 6 (15)b
Pemetrexed 44 1 (2) 1 (2) 21 (48) 18 (41) 3 (7)c
a Given that the protocol did not require regular tumor assessments, it is possible
that an interim scan may have identified patients who had a better tumor response than
that reported here. In addition, patients were not required to have measurable disease at
baseline.
b One patient had rapid progression and died 4 d after the start of the study. A second
patient received no study treatment; time to progression was 4 d with subsequent death. A
third patient had a prolonged QTc interval at screening; the patient stopped treatment after
1 wk of AZD6244 (progression occurred 219 d after randomization). A fourth patient
progressed and died due to respiratory failure 25 d after randomization. A fifth patient
withdrew their consent, and a sixth patient had rapid progression and subsequently died 8 d
after randomization.
c One patient died 63 d after randomization from a myocardial infarction before the
follow-up scan. A second patient did not receive study treatment; their time to
progression was 57 d and they died 146 d after randomization. A third patient withdrew
their consent.
TABLE 3. Number of Patients with the Most Frequently
Reported (10% of All Patients) Treatment-Related Adverse
Events (EFS Population)
Preferred Term
Patients,
n (%)
AZD6244
(n  40)
Pemetrexed
(n  41)
Nonhematologic adverse events
Dermatitis acneiform 17 (43) 7 (17)
Diarrhea 12 (30) 2 (5)
Nausea 7 (18) 9 (22)
Vomiting 7 (18) 7 (17)
Fatigue 5 (13) 15 (37)
Anorexia 3 (8) 6 (15)
Hematologic adverse events
Anemia 2 (5) 12 (29)
Neutropeniaa 0 7 (17)
a As per the study protocol, abnormalities in the laboratory findings were only to be
reported as adverse events if they fulfilled any criterion for a serious adverse event, if
the laboratory abnormalities caused the patient to discontinue from the study, or if the
investigator insisted that the abnormality should be reported as an adverse event.
Therefore, the number of reported adverse events of neutropenia may not match the
results derived from the laboratory findings.
FIGURE 2. Comparison between AZD6244 and pem-
etrexed in terms of progression-free survival (ITT [in-
tent to treat] population).
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a disease progression event (59% versus 70%, respectively;
HR  1.35; two-sided 80% CI  0.93–1.94; two-sided 95%
CI 0.77–2.36; p 0.30) and PFS (HR 1.08; two-sided 80%
CI  0.75–1.54; two-sided 95% CI  0.62–1.86; p  0.79).
Response rates were also similar in patients receiving either
AZD6244 or pemetrexed (5.0% versus 4.5%, respectively).
Confidence intervals were typically wide for comparison of the
efficacy analyses in this study in light of the small patient
numbers. Furthermore, it should be noted that the PFS and tumor
response data were not robust because the protocol did not
require regular tumor assessments, and patients were not re-
quired to have measurable disease at baseline.
The efficacy of pemetrexed observed in this study
was consistent with previous experience with pemetrexed
in the second- and third-line treatment of advanced
NSCLC.12,17,18 Response rates for 3-weekly 500 mg/m2
pemetrexed in previous studies were slightly higher than
that in this study, ranging from 7.1 to 11.2%. Median PFS
was 90 days in this study, compared with 2.6 months in the
study by Cullen et al.,18 2.9 months in the study by Hanna
et al.,12 and 3.0 months in the study by Bearz et al.17
Of note, a number of recent studies have shown that
tumor histology impacts on the efficacy of pemetrexed,
with better efficacy reported in patients with nonsquamous
tumors than in those with squamous cell carcinomas.19–21
A retrospective analysis of the study by Hanna et al.,12,21
for example, found that pemetrexed efficacy varied be-
tween squamous and nonsquamous histologic subtypes in
terms of overall survival (6.2 versus 9.3 months), PFS (2.3
versus 3.1 months), and tumor response rates (2.8% versus
11.5%). Accordingly, the second-line indication for pem-
etrexed was revised in 2008 to include only patients with
nonsquamous advanced or metastatic NSCLC.22 This
study, which began before the pemetrexed label change,
did not exclude patients with squamous histology and did
not stratify patients by histologic status; therefore, the
activity of pemetrexed in the nonsquamous population for
which the drug is currently indicated may be underesti-
mated.
As with pemetrexed, it has been suggested that
sensitivity to AZD6244 may also be higher in certain
patient subgroups. A recent in vitro study demonstrated a
tendency toward sensitivity to AZD6244 in cell lines
harboring BRAF or RAS gene mutations compared with
those with wild-type genes.23 A similar observation was
reported in a recent phase II study comparing AZD6244
with temozolomide in patients with advanced or metastatic
melanoma in which five of six (83%) patients who
achieved confirmed partial responses with AZD6244 had
BRAF mutation-positive tumors.24 It was unknown at the
start of this study which mutations may confer sensitivity
to AZD6244, and therefore, a broad population of patients
was assessed.
AZD6244 was generally well tolerated, which was
reflected by the low number of dose reductions or treat-
ment interruptions. Most patients in both treatment arms
experienced at least one AE, and the number and types of
AEs were consistent with the nature of the study treat-
ments and the disease under study. The AE profile varied
between the treatment groups. AZD6244 was associated
with more dermatitis acneiform and diarrhea than pem-
etrexed, which is consistent with the previously reported
safety profile for AZD6244.10 Fatigue, anemia, neutrope-
nia, and anorexia were more commonly associated with
pemetrexed than AZD6244, which is also comparable with
the safety profile for pemetrexed reported in the litera-
ture.12,17,18 Consistent with its AE profile in this study,
pemetrexed was also associated with greater and more
serious decreases in hemoglobin levels than AZD6244, as
well as greater decreases in the number of white blood
cells, neutrophils, and platelets.
CTCAE grade 3 or higher AEs were experienced by
a similar number of patients in both treatment groups,
although CTCAE grade 4 AEs were more prevalent in the
pemetrexed arm of the study. The rates of CTCAE grade
3/4 neutropenia and anemia observed with pemetrexed in
this study (10% and 10%, respectively) were higher than
those reported in the studies by Hanna et al., Bearz et al.,
and Cullen et al.,12,17,18 which reported grade 3/4 neutro-
penia in 5.3%, 1.9%, and 2.1% of patients and grade 3/4
anemia in 4.2%, 1.9%, and 1.4% of patients, respectively.
Serious adverse events were experienced by more patients
in the pemetrexed arm of this study than in the AZD6244
arm (17% versus 10%, respectively), although in both
treatment groups, SAEs were indicative of a population
with advanced NSCLC. Overall, the safety and laboratory
results of this study did not indicate any new safety
concerns for AZD6244.
In conclusion, the results of this study showed that
the oral MEK1/2 inhibitor AZD6244 is a well-tolerated
treatment regimen, with clinical activity as a second- or
third-line treatment in a broad population of patients with
advanced NSCLC. As a single agent, there was no indica-
tion of superiority to standard treatment with pemetrexed
in this randomized phase II study. Further development of
AZD6244 in NSCLC should focus on patients with dem-
onstrated mutations of the BRAF or RAS oncogenes or on
the development of rational combination regimens.
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